Del Re Marzia, Latiano Tiziana, Fidilio Leonardo, Restante Giuliana, Morelli Franco, Maiello Evaristo, Danesi Romano
Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, 55, Via Roma, 56126 Pisa, Italy.
Medical Oncology Unit, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Foggia Italy.
EPMA J. 2017 Mar 7;8(1):69-73. doi: 10.1007/s13167-017-0080-z. eCollection 2017 Mar.
The standard treatment of testicular germ cell tumors is based on the combination of bleomycin, etoposide, and cisplatin (PEB). However, this treatment may be associated with severe adverse reactions, such as hematological and non-hematological toxicities. Here, we report a case of a patient suffering from severe PEB-related toxicities, to whom pharmacogenetic analyses were performed, comprising a panel of genes involved in PEB metabolism. The analysis revealed the presence of a complex pattern of polymorphisms in , (TA)6/7, , and . The present case shows that a pharmacogenetic approach can help in the management of adverse drug reactions in order to predict, prevent, and personalize treatments.
睾丸生殖细胞肿瘤的标准治疗方法是基于博来霉素、依托泊苷和顺铂（PEB）的联合使用。然而，这种治疗可能会伴有严重的不良反应，如血液学和非血液学毒性。在此，我们报告一例患有严重PEB相关毒性的患者，对其进行了药物遗传学分析，包括一组参与PEB代谢的基因。分析显示在、（TA）6/7、和中存在复杂的多态性模式。本病例表明，药物遗传学方法有助于管理药物不良反应，以预测、预防和个性化治疗。
